Ferring Pharmaceuticals and Celmatix announced a new genomics collaboration based on Celmatix’s proprietary knowledge base technology. This will be used to explore whether women’s responses to ovarian stimulation during in vitro fertilisation (IVF), which can vary greatly, are linked to individual characteristics of their genome. These insights could help to reduce adverse and life-threatening outcomes such as ovarian hyper-stimulation syndrome, and lower the rates of IVF cycle cancellation due to poor treatment response.